StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGX – Get Rating) in a report released on Monday. The brokerage set a "hold" rating on the biotechnology company's stock.
Jaguar Health Stock Down 2.9 %
Shares of JAGX stock opened at $0.16 on Monday. The stock has a market cap of $18.73 million, a P/E ratio of -0.14 and a beta of 1.65. Jaguar Health has a one year low of $0.15 and a one year high of $2.66. The stock has a fifty day moving average price of $0.24 and a 200 day moving average price of $0.36. The company has a debt-to-equity ratio of 8.47, a current ratio of 1.02 and a quick ratio of 0.73.
Get
Jaguar Health alerts:
Jaguar Health (NASDAQ:JAGX – Get Rating) last issued its earnings results on Monday, August 22nd. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.10. The firm had revenue of $2.92 million during the quarter. Jaguar Health had a negative return on equity of 486.62% and a negative net margin of 652.35%. Analysts predict that Jaguar Health will post -0.67 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Citigroup Inc. bought a new position in shares of Jaguar Health during the first quarter valued at $34,000. Goldman Sachs Group Inc. lifted its holdings in shares of Jaguar Health by 153.3% during the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company's stock valued at $39,000 after acquiring an additional 33,148 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company's stock valued at $120,000 after acquiring an additional 141,796 shares during the period. Millennium Management LLC lifted its holdings in shares of Jaguar Health by 152.3% during the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company's stock valued at $157,000 after acquiring an additional 321,795 shares during the period. Finally, Virtu Financial LLC lifted its holdings in shares of Jaguar Health by 76.1% during the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company's stock valued at $162,000 after acquiring an additional 99,073 shares during the period. 7.40% of the stock is owned by institutional investors.
About Jaguar Health
(Get Rating)
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Recommended Stories
- Get a free copy of the StockNews.com research report on Jaguar Health (JAGX)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.
